Chlamydia Infection Diagnostics Market Size

  • Report ID: 6570
  • Published Date: Oct 18, 2024
  • Report Format: PDF, PPT

Chlamydia Infection Diagnostics Market Size

Chlamydia Infection Diagnostics Market size was USD 1.6 billion in 2024 and is estimated to reach USD 4.1 billion by the end of 2037, expanding at a CAGR of 7.5% during the forecast period, i.e., 2025-2037. In 2025, the industry size of chlamydia infection diagnostics will be valued at USD 1.7 billion.

Chlamydia is asymptomatic and many young individuals are unaware of STDs and associated risks. This lack of awareness contributes to its higher transmission rates, fuelling the need for advanced chlamydia infection diagnostic solutions. As the prevalence rate increases, the need for effective diagnostic solutions to identify and treat infections promptly booms. This demand drives innovation and investment in chlamydia testing technologies.

For instance, according to the World Health Organization (WHO), around 128.5 million new chlamydia infection cases were registered among the age group of 15 to 49 across the world, in 2022. Particularly for this demographic, the prevalence rate among women was 4.0% and 2.5% in men. Untreated chlamydia can cause serious issues such as HIV or other STIs. To minimize the prevalence rate of chlamydia, public and private healthcare organizations are implementing targeted screening programs and educational campaigns, further boosting the sales of diagnostic solutions.


Chlamydia Infection Diagnostics Market Size
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 6570
  • Published Date: Oct 18, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The global chlamydia infection diagnostics market will be valued at USD 1.7 billion in 2025.

Expanding at a CAGR of 7.5%, the global market is expected to increase from USD 1.6 billion in 2024 to USD 4.1 billion by 2037.

Some leading companies are Visby Medical, Abbott Laboratories, Thermo Fisher Scientific Inc., Trinity Biotech Plc., Qiagen Inc., and Becton, Dickinson and Company.

The genital chlamydia infection segment is estimated to capture a strong 72.5% of the market share through 2037.

North America is expected to hold 39.0% of the global market share through 2037.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample